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The diagnosis of mesothelioma is not always straightforward, despite known
immunohistochemical markers and other diagnostic techniques. One reason for the
difficulty is that extrapleural tumors resembling mesothelioma may have several possible
etiologies, especially in cases with no meaningful history of amphibole asbestos
exposure. When the diagnosis of mesothelioma is based on histologic features alone,
primary mesotheliomas may resemble various primary or metastatic cancers that have
directly invaded the serosal membranes. Some of these metastatic malignancies,
particularly carcinomas and sarcomas of the pleura, pericardium and peritoneum, may
undergo desmoplastic reaction in the pleura, thereby mimicking mesothelioma, rather
than the primary tumor. Encasement of the lung by direct spread or metastasis,
termed pseudomesotheliomatous spread, occurs with several other primary cancer
types, including certain late-stage tumors from genetic cancer syndromes exhibiting
chromosomal instability. Although immunohistochemical staining patterns differentiate
most carcinomas, lymphomas, and mestastatic sarcomas from mesotheliomas, specific
genetic markers in tumor or somatic tissues have been recently identified that may also
distinguish these tumor types from asbestos-related mesothelioma. A registry for genetic
screening of mesothelioma cases would help lead to improvements in diagnostic criteria,
prognostic accuracy and treatment efficacy, as well as improved estimates of primary
mesothelioma incidence and of background rates of cancers unrelated to asbestos that
might be otherwise mistaken for mesothelioma. This information would also help better
define the dose-response relationships for mesothelioma and asbestos exposure, as well
as other risk factors for mesothelioma and other mesenchymal or advanced metastatic
tumors that may be indistinguishable by histology and staining characteristics.
Keywords: germ cell tumors, synovial sarcoma, pericardial mesothelioma, mullerian tissue cancers, chromosomal
instability, human, asbestos
INTRODUCTION
By far, the most extensively investigated cause of mesothelioma
is asbestos exposure (Sporn and Roggli, 2004). Asbestos occurs
in two mineralogic forms: commercially used amphiboles (e.g.,
commercially available amosite and crocidolite) and chrysotile.
Amosite and crocidolite are considerably more persistent in tis-
sue than is chrysotile, which disappears from lung tissue rapidly
(Bernstein et al., 2005, 2010, 2011). This difference in bioper-
sistence is believed to be the one of reasons that mesothelioma
incidence rates are much higher in those who used or manu-
factured products with amosite and crocidolite, when compared
to those exposed to only chrysotile (Churg, 1998; Hodgson and
Darnton, 2000; Yarborough, 2006).
Although there is some debate regarding the potency gradi-
ent between chrysotile and asbestos fiber types, most agree that
amphiboles are more toxic on a fiber-to-fiber basis (Hodgson and
Darnton, 2000, 2010; Berman and Crump, 2008a,b). Some epi-
demiologic observations suggest that the incidence of mesothe-
lioma caused by asbestos exposure peaked between about 1990
and 2010, because the highly potent amphibole exposures were
largely curtailed in the 1960s and the typical latency period of
20–40 years since first exposure has now transpired (Hemminki
and Li, 2003; Hillard et al., 2003; Price and Ware, 2004; Weill
et al., 2004; Burdorf et al., 2007; Teta et al., 2008; Harding and
Darnton, 2010). Epidemiologic observations also suggest a much
lower, if not zero, mesothelioma potency for the more promi-
nent chrysotile exposures from various sources and products in
subsequent years (Hodgson and Darnton, 2000, 2010; Berman
and Crump, 2003, 2008a,b; Goodman et al., 2004; Laden et al.,
2004; Gibbs and Berry, 2008; Sichletidis et al., 2008). If this is
true, it suggests that sometime in the near future there may be
a substantial decline in the number of asbestos-induced mesothe-
lioma cases. Consequently, there will be a greater need to clinically
distinguish and better understand the etiology of mesothelioma
cases unrelated to asbestos exposure.
While only perhaps 10–20% of pleural mesothelioma cases in
the past decade are reportedly due to causes other than asbestos
exposure (Sporn and Roggli, 2004), the risk factors for peritoneal
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mesothelioma are far more diverse, with less than half of the
cases in recent case series explained by heavy amphibole expo-
sures (Neumann et al., 2001; Hillard et al., 2003; Weill et al.,
2004; Reid et al., 2005; Bofetta and Stayner, 2006; Bofetta, 2007;
Larson et al., 2007; Magnani et al., 2007; Gibbs and Berry, 2008).
Pericardial mesothelioma is far less common than the pleural and
peritoneal forms and has no strong or consistent association with
asbestos exposure (Papi et al., 2005; Luk et al., 2008). In addition,
unlike pleural mesothelioma, peritoneal and pericardial mesothe-
liomas often occur in younger individuals with no known or
substantial source of past asbestos exposure (Sporn and Roggli,
2004; Papi et al., 2005; Luk et al., 2008). Recent reviews acknowl-
edge that asbestos is not the sole cause of pleural and peritoneal
mesothelioma, with erionite and ionizing radiation being estab-
lished causes and the relatively low frequency of mesothelioma
among more highly exposed individuals indicating that genetic
susceptibility factors and/or co-carcinogens may play an impor-
tant role (Neri et al., 2005; Testa et al., 2011; Jasani and Gibbs,
2012; Jean et al., 2012; Tallet et al., 2013).
Rates of peritoneal mesothelioma have stayed relatively flat
in developed countries during the past two decades, in contrast
to the dramatic rise in pleural mesothelioma rates from about
the 1960s through at least the mid-1990s that was associated
with asbestos use in prior decades (Hemminki and Li, 2003;
Leigh, 2003; Weill et al., 2004; Burdorf et al., 2007; Teta et al.,
2008; Moolgavkar et al., 2009; Harding and Darnton, 2010). This
divergence suggests that asbestos is not likely to be among the
current major causes of peritoneal mesothelioma. In fact, there
is emerging evidence that some of the tumors initially diagnosed
as peritoneal mesotheliomas are in actuality a cancer with another
origin. Peritoneal tumors may easily be misclassified as they often
result from metastatic disease originating in other organs and are
typically discovered at late stages when such tumors may exhibit
mixed pathological characteristics that do not closely resemble
the original tumor cell type (Pass et al., 2005; Burdorf et al.,
2007). It has even been suggested that peritoneal mesothelioma
in younger individuals (e.g., under age 50) may represent a dis-
tinctly different disease entity; one that is more curable and more
likely related to gonadal cancers, and so, not plausibly attributed
to asbestos exposure (Weill et al., 2004; Hodgson et al., 2005;
Larson et al., 2007).
Because mesothelioma lacks a unique and distinctive pattern
of histological features, the diagnosis is often tentative and based
primarily on a defined pattern of staining with immunohisto-
chemical markers (Ordonez, 1998; Cappello and Barnes, 2001).
While most tumor presentations can be distinguished by the pres-
ence/absence of these specific immunohistochemical markers, in
many cases a definitive staining pattern is lacking. The difficul-
ties sometimes encountered with mesothelioma diagnosis based
on only cytology and immunohistochemical staining pattern are
summarized in Figure 1.
Although a highly specific biomarker for mesothelioma has
not yet been demonstrated, a variety of case series reports have
been used to identify patterns of positive and negative staining
characteristics that are “consistent with” malignant mesothe-
lioma. The primary goal in distinguishing epithelioid types of
mesothelioma involves a staining pattern that is generally not seen
in adenocarcinomas; this includes positive staining for panker-
atin, calretinin, keratin 5/6, and WT1 (but not necessarily all of
these), and negative staining for CEA, CD15, Ber-EP4 Moc-31,
TTF-1, and B72.3 (Ordonez, 1998; Cappello and Barnes, 2001;
Pass et al., 2008). But the heterogeneous histology of mesothe-
lioma (e.g., the involvement of epithelial cells, spindle cells or
both cell types) can lead to inconsistent or ambiguous staining
patterns that overlap with other tumor types, e.g., certain soft tis-
sue sarcomas (Nicholson et al., 1998; Cappello and Barnes, 2001;
Miettinen et al., 2001). In addition, the chromosomal instability
of metastatic tumors that often leads to more primitive cell types
with indistinct staining patterns may in some cases overlap with
those of mesothelioma or soft tissue sarcoma (Morin et al., 2005).
To date, searches for genetic aberrations associated with malig-
nant mesothelioma have failed to identify a highly specific chro-
mosomal abnormality, although several associated lesions based
on newer techniques like micro-RNA expression, DNA methyla-
tion, telomere status, micronucleus formation, and gene expres-
sion profiling are under investigation (Bott et al., 2011; Testa
et al., 2011; Jean et al., 2012). In contrast to many other types
of solid tumor, mesotheliomas generally lack mutations of the
fundamental tumor suppressor genes, p53 and RB. Only a few
molecular defects have been identified in mesotheliomas thus far.
Pisick and Salgia (2005) reviewed the literature and concluded
that while there are several different genetic and signal path-
way alterations that can occur in malignant mesothelioma cells
and cell lines, these changes are heterogeneous, and therefore not
clearly useful for diagnostic purposes at this time. These authors
noted that transformation occurs either by direct stimulation of
pathways activated by receptor tyrosine kinases or by a loss of
genetic material containing tumor suppressor genes that prevent
unchecked cell proliferation. The more commonly noted losses
occur on the short arms of chromosomes 1 (notably 1p21–p22),
3 (notably 3p21.3), and 9 (notably 9p14/p16), and on the long
arms of chromosomes 6 (notably 6q14–q21, 6q16.6–q21, 6q21–
q23.2, and 6q25), 15 (notably 15q11.1–q15), and both arms of
chromosome 22 (Pisick and Salgia, 2005; Pass et al., 2008). Loss of
a copy of chromosome 22 is thought to be the single most consis-
tent karyotypic alteration seen in malignant mesothelioma (Pass
et al., 2008). Unfortunately, these patterns of genetic loss also rep-
resent genetic variations seen in more common forms of cancer,
such as non-Hodgkin’s lymphoma, breast, ovarian, prostate, lung
and colon cancers (Pisick and Salgia, 2005).
A more recent review on molecular changes observed in
mesothelioma by Jean et al. (2012) summarized findings of
emerging research on possible genetic markers. These authors
identified a slightly wider range of associated chromosomal alter-
ations including losses at 1p, 3p, 4q, 6q, 13p, 14q, and 22q, and
gains at 1q, 5p, 7p, 8q, and 17q and noted thatmore specificmuta-
tions on chromosome 22 (e.g., deletions at the neurofibromatosis
2 locus, 22q12), chromosome 9 (e.g., INK4 genes, specifically
deletions at cyclin-dependent kinase inhibitor genes CDKN2A
and CDKN2B at 9p21.3), and chromosome 17 (TP53 gene dele-
tion at 17p13.1, though less common) have been associated
with mesothelioma in recent reports. However, these mutations
occur with several other cancer types (Jean et al., 2012). They
noted a new association between mesotheliomas and increased
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FIGURE 1 | Difficulties with diagnosis of primary mesothelioma using only cytology and immunohistochemical staining pattern.
microRNA expression of certain types (MiR-31, -141, -192, -193,
-200a-c, -203, -205, and -429); greater DNA methylation at cer-
tain loci, and increases inmarkers of telomere lengthmaintenance
mechanisms were also reportedly associated with mesotheliomas
(Ivanov et al., 2010; Jean et al., 2012). While many of these new
associations appear promising as adjuncts to current immunohis-
tochemical staining techniques in discerning mesothelioma from
other cancer types, further research is needed to determine their
specificity and reliability in refining diagnosis, treatment, and
prognosis for mesothelioma.
Other recent observations on mesothelioma genetic mark-
ers have focused on mesenchymal membrane receptor tyrosine
kinases that dirve downstream cell signaling of cell prolifera-
tion, cell cycle control, survival and differentiation (Lemmon and
Schlessinger, 2010). First, there is recent evidence suggesting that
telomere status and telomere maintenance mechanisms tied to
P53, ATRX and DAXX mutations may be helpful in distinguish-
ing more aggressive mesotheliomas (Durant, 2012; Gocha et al.,
2013; Tallet et al., 2013). Positive telomerase activity is observed in
91–100% of pleural mesotheliomas in two studies (Dhaene et al.,
1998; Au et al., 2011), and telomerase-independent pathways for
telomere lengthening through DNA damage repair mechanisms
(ALT positive cells) are more commonly observed in sarcomatoid
tumors (Heaphy et al., 2011; Durant, 2012; Hu et al., 2012) and
persons with multiple endocrine neoplasia type 1 (Gocha et al.,
2013). Second, the mutations leading to telomere lengthening
and survival of clonally expanding mesothelioma cells using ALT
mechanisms are reported to form ALT-associated promyelocytic
bodies that may be akin to micronuclei observed in tumor cells
and blood polynucleated lymphocytes with exposure to asbestos
(Dopp et al., 1995; Bolognesi et al., 2005; Martini et al., 2011).
Third, soluble mesothelin-related peptides are overexpressed in
persons with mesothelioma (Robinson et al., 2003; Scherpereel
et al., 2006) and have been associated with increased micronu-
clei in peripheral lymphocytes (Martini et al., 2011). And fourth,
germline mutations in nuclear deubiquitinase BRCA1-associated
protein 1 (BAP1) have been observed in familial clusters of
mesothelioma not necessarily linked to asbestos (Testa et al.,
2011) and in a fraction of pleural mesotheliomas in other case
series (Bott et al., 2011; Jean et al., 2012; Tallet et al., 2013).
These more recent associations are all tied into loss of normal
cell signaling that occurs in a variety of cancer types, but further
investigations may provide more specific genetic markers to help
better distinguish mesothelioma diagnosis, treatment, and prog-
noses in the future (Bott et al., 2011; Jean et al., 2012; Gocha et al.,
2013).
Given the preceding issues, it is important to collect and more
thoroughly evaluate genetic evidence for mesothelioma cases,
particularly in younger cases or those with little or no known
amphibole asbestos exposure. Genetic screening in conjunction
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with assessment of histology and immunohistochemical staining
patterns in these cases may result in more definitive identification
of the true tissue/cell-type of origin, thereby avoiding misdiag-
nosis of mesothelioma. This, in turn, would allow for a better
identification of tumor-specific risk factors and thereby increase
the possibility of a more effective treatment regimen specific
for those cancers that are not a true mesothelioma. Screening
for genetic aberrations corresponding to tumor types known to
mimic mesothelioma would seem to be particularly important in
cases where no occupational asbestos exposure has been identi-
fied, in cases involving an individual under 50 years old, and in
cases with no evidence of pleural plaques, asbestosis, or elevated
lung asbestos fiber counts.
Genetic testing of suspected mesothelioma cases with non-
distinct staining patterns is apparently an infrequent medical
consideration despite the potential value to the patient and to
medical science in the form of learning more about the genetics
underlying mesothelioma and other tumors types with histologi-
cal resemblance1. Additional factors that can provide important
evidence reflecting on the likelihood of misdiagnosis and/or
unlikely association with asbestos exposure for tentatively diag-
nosed mesothelioma cases are provided in Figure 2.
The purpose of this paper is to set out the scientific basis
for a registry-based research protocol for the collection of med-
ical information and tissue samples to refine medical knowledge
on mesothelioma diagnosis, prognosis, and rates. The basis for
genetic testing that may distinguish specific cancer types prob-
ably unrelated to asbestos exposure is reviewed, and the utility
of a registry-based research program to enhance medical knowl-
edge regarding the etiology of general and specific subtypes of
mesothelioma is explored.
BASIS FOR GENETIC TESTING OF MESOTHELIOMA AND
HISTOLOGICALLY SIMILAR TUMORS
GERM CELL TUMORS AND MESOTHELIOMA
Advanced stage extragonadal germ cell tumors (GCTs) are known
to commonly occur in, or metastasize to, tissues along the body
midline from the pineal gland to the sacrum. Due to their multi-
potential nature they can exhibit features, both for histology and
immunohistochemical markers, of primary pleural or peritoneal
malignant mesothelioma. Mesothelioma of the tunica vaginalis is
an example of this occurring within the testicle, yet little attention
has been given to potential metastatic forms of this tumor and/or
1Each of the research categories proposed in this manuscript is based on a
compilation of notes from actual mesothelioma claims with findings that sup-
ported the alternative diagnosis. However, current privacy laws in the United
States prevent reporting specific details of these cases here. Establishing a
registry-based research program as proposed in this paper would generate the
epidemiologic and clinical information for the improvement of diagnosis and
identification of risk factors for this cancer in a manner that protects patient
privacy. A registry would provide a neutral setting outside of the litigation
arena where legal maneuvering would not hamper necessary data collection
and analysis. Unfortunately, it has been the experience of one of the authors
(BDK) that information that could improve disease causation analysis for
mesothelioma cases has been blocked when a legal case has been filed. These
attorneys may not realize that a more definitive diagnosis might lead to a more
effective treatment and a better prognosis for the affected individual.
to extragonadal GCTs that originate from mutated embryonic
cells of the urogenital ridge that may be mistakenly diagnosed
as a mesothelioma of the peritoneum or pleura. The occurrence
of mesothelioma in children and adolescents without signifi-
cant or identifiable asbestos exposure (Fraire et al., 1988; Coffin
and Dehner, 1992; Niggli et al., 1994; Hubbard, 1997) could
plausibly represent a GCT or other congenital/genetic mutations
affecting mesenchymal tissues, especially given the much higher
background incidence of GCTs relative to that of mesothelioma.
GCTs can arise from germ cell tissues in the testes, the prostate,
and other tissue locations (extragonadal GCT) as a result of a
mutation and abnormal migration of germ cells during embry-
onic development (Blossom et al., 1997; Sarma et al., 2006).
Blossom et al. (1997) have explained that extragonadal GCTs
occur along the body’s midline from the presacral areas and
retroperitoneum up to the cranium (pineal gland), a pattern that
corresponds to the embryologic urogenital ridge extending along
the mediastinum and peritoneum from vertebrae C-6 to L-4.
Extragonadal GCTs result from malignant transformation of ger-
minal elements that are displaced to extragonadal sites in the
absence of any gonadal primary tumor (Blossom et al., 1997).
There is no plausible etiologic role of asbestos exposure in the
development of extragonadal GCTs.
Blossom et al. (1997) have also noted that approximately 90%
of malignant extragonadal GCT occur in men, most of which are
diagnosed in the third decade of life or later. While the lifetime
probability of developing a GCT (most of which originate from
the testes) is only about 0.2% in Caucasian males in the United
States, this lifetime risk is far greater than that of mesothelioma.
Thus, potential misdiagnosis of these tumors might represent a
substantial portion of the tumors mistakenly diagnosed as pleu-
ral or peritoneal mesothelioma in males, and may falsely increase
the estimated background incidence of mesothelioma. The cause
of these tumors is unknown but they are most likely explained by
genetic mutation events in early embryonic development (Bosl
et al., 1997). Individuals with a history of cryptorchidism are
known to exhibit a significantly increased risk of testicular GCT
(Bosl et al., 1997; Motzer and Bosl, 2005), as are brothers of
individuals with GCTs (Kumar et al., 2005a; Motzer and Bosl,
2005).
The multi-potential nature of GCTs leads to a diverse patho-
logical appearance including combined epithelial and spindle cell
presentations that might be mistaken for mesothelioma (Blossom
et al., 1997; Bosl et al., 1997; Motzer and Bosl, 2005). Due to this
diversity of GCTs, and especially for advanced stage metastatic
tumors, common stains and immunohistochemical markers may
be unhelpful in identifying the origins of extragonadal GCTs.
Fortunately, there are characteristic DNA changes in some tumors
affecting chromosome 12 (iso-12p) that may help one to diagnose
tumors originating from germ cells from gonadal or extragonadal
sites (Bosl et al., 1997; Kumar et al., 2005a; Sarma et al., 2006).
Since GCTs are not inhibited in their lines of differentiation, most
presentations include two or more histologic patterns (e.g., mixed
sarcomatoid and epithelioid as seen with mesothelioma), and
males with a history of cryptorchid and dysgenetic testes show
familial clustering and a higher frequency of intratubular GCTs
(Kumar et al., 2005a).
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FIGURE 2 | Additional factors to consider in evaluating suspected asbestos-related mesothelioma.
MULLERIAN TISSUE TUMORS AND MESOTHELIOMA
Mullerian tissue tumors, of both breast and ovarian/adnexal ori-
gins, include certain mesenchymal subtypes that can spread to
either the pleura or peritoneum in females. Breast cancer is a com-
mon metastatic tumor affecting the pleura in females (Winston
et al., 2000; Kolschmann et al., 2005), and ovarian/adnexal can-
cers are also reported to spread to both the pleura and the
peritoneum at advanced stages (Cormio et al., 2003). Breast
cancer risk factors such as BRCA phenotype are now known
to carry risks for certain female gonadal cancers that mimic
mesothelioma (Hankinson and Danforth, 2006; Cannistra et al.,
2008). More specifically, primary papillary serous carcinomas
are among the most common forms of aggressive cancer types
that originate in female gonadal tissues (i.e., ovarian surface
epithelium, fallopian tube epithelium and fimbria, or mulle-
rian tissue gonadal remnants) and can be difficult to distinguish
from advanced forms of mesothelioma when the immunohisto-
chemical staining pattern is ambiguous (Kannerstein et al., 1977;
Bannatyne and Russell, 1981; Raju et al., 1989; Altaras et al.,
1991; Fox, 1993; Alvarado-Cabrero et al., 1997; Crum et al.,
2007). The ovarian surface epithelium is comprised of a spe-
cialized type of mesothelial cell forming embryonic mesoderm
tissue that is a direct descendent of the coelomic epithelium
of the embryonic gonadal ridge and of the mullerian duct sys-
tem (Lauchlan, 1972; Parmley and Woodruff, 1974; Kannerstein
et al., 1977; Fox, 1993; Katabuchi and Okamura, 2003; Piek et al.,
2004).
Altaras et al. (1991) explained some of the history behind
papillary serous carcinomas (PSC) being ultimately distinguished
as separate clinical entities from mesotheliomas. Specifically, the
peritoneal location of PSC is explained by the common coelomic
ancestry of the mullerian duct epithelium and the peritoneal
mesothelium. Mullerian differentiation can occur in a variety of
metaplastic and neoplastic ways in diverse tissue locations, such as
PSC, ovarian tumors of common epithelial origin, endometrio-
sis, endosalpingiosis, and epithelial inclusions of the ovary and
lymph nodes (Altaras et al., 1991). Diffuse PSC of the peri-
toneum without overt involvement of the ovary was initially
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described as malignant mesothelioma, until Kannerstein et al.
(1977) identified histological criteria that distinguished PSC
from mesotheliomas and from all extraovarian epithelial tumors.
However, PSC of peritoneal and ovarian origin remain indis-
tinguishable from each other by histopathology (Altaras et al.,
1991).
More advanced-stage tumors and metastases from mullerian
cells may become more primitive (undifferentiated) such that the
tumor cell histology and immunohistochemical markers of the
ovarian surface epithelial cells cannot be readily distinguished
from less specialized mesothelial tumors that may originate in
the peritoneal lining tissue (Hernandez et al., 1984; August et al.,
1985; Cramer et al., 1987; Lund et al., 1991; Sakamoto et al., 1994;
Gilks et al., 2008).
Some key tumor immunohistochemical markers (e.g., posi-
tive calretinin, CK7, and WT-1, with negative CEA) and cellular
characteristics (epithelioid, poorly differentiated) are commonly
seen for both mesothelioma and PSC (Fox, 1993; Schorge et al.,
2000; Shimizu et al., 2000; Al-Hussaini et al., 2004; McCoubrey
et al., 2005; Kobel et al., 2008). Indeed, PSC in many ways can
mimic epithelioid mesothelioma, but unlike mesothelioma, PSC
is linked to hereditary and sporadic mutations of two breast can-
cer susceptibility genes (BRCA-1 and BRCA-2). Primary epithelial
cancers of the fallopian tubes (particularly the fimbria) appear
to be linked to more aggressive and early-onset PSC in women
with the BRCA-1 mutation (Sobol et al., 2000; Zweemer et al.,
2000; Aziz et al., 2001; Paley et al., 2001; Levine et al., 2003; Piek
et al., 2003; Finch et al., 2006; Medeiros et al., 2006; Kindelberger
et al., 2007), while ovarian surface epithelium tumors have been
linked to both BRCA-1 and BRCA-2 mutations (Werness et al.,
2000; Colgan et al., 2001, 2002; Piura et al., 2001; Risch et al.,
2001; Agoff et al., 2002; Brose et al., 2002; Geisler et al., 2002;
Hilton et al., 2002; Cass et al., 2005). More advanced PSC tumors
originating from ovarian surface epithelium or tubal fimbria
epithelium are subject to genomic instability, loss of WT-1 gene
expression, and the presence of both BRCA and p53 mutations,
sometimes making the site or origin difficult to distinguish in
more advanced stages of the disease (Schorge et al., 2000; Piek
et al., 2004; Kindelberger et al., 2007; Lee et al., 2007; Gilks et al.,
2008).
Since PSC can originate as an occult mullerian neoplasm that
commonly proliferates at other peritoneal sites (Colgan et al.,
2001, 2002; Cass et al., 2005; Powell et al., 2005; Finch et al., 2006;
Chand et al., 2007), the pathological (histology and staining) eval-
uation of PSC often does not identify the original tumor site and
should be augmented with detailed analysis of the patient’s clin-
ical and family history and BRCA phenotype in order to assign
the final diagnosis with reasonable medical certainty (Risch et al.,
2001; Piek et al., 2004; Kindelberger et al., 2007; Gilks et al.,
2008). BRCA-positive families are noted to have higher cancer
rates affecting the colon, prostate, pancreas and peritoneum, as
well as melanoma (Struewing et al., 1997; Frank, 2001; Paley et al.,
2001; Al-Hussaini et al., 2004). Three familial genetic syndromes
associated with excess ovarian cancer risk have been identified:
certain BRCA-1 or BRCA-2 mutations result in Breast Ovarian
Cancer Syndrome, Site-Specific Ovarian Cancer Syndrome, and
Hereditary Non-Polyposis Colon Cancer (or Lynch II Syndrome)
which are associated with mutations in DNA mismatch repair
genes in affected families (Muto, 2005).
In contrast, PSC has not been specifically associated with
asbestos exposure (Fox, 1993), and peritoneal mesothelioma are
predominantly associated with relatively high exposures to pri-
marily amphibole forms of asbestos (Sporn and Roggli, 2004;
Bofetta and Stayner, 2006; Yarborough, 2007; Gibbs and Berry,
2008).
CONGENITAL HEART DISEASE AND PERICARDIAL MESOTHELIOMA
Pericardial mesothelioma is estimated to comprise only 0.7–1% of
all mesotheliomas (Papi et al., 2005; Molina Garrido et al., 2006)
and lacks a specific immunohistochemical staining pattern that
would distinguish this lesion from mesotheliomas originating at
other sites (Reis-Filho et al., 2002; Papi et al., 2005). In contrast to
pleural mesothelioma, the association of asbestos exposure with
pericardial mesothelioma is unclear (Eren and Akar, 2002; Val-
Bernal et al., 2002; Lagrotteria et al., 2005; Papi et al., 2005; Luk
et al., 2008). Although a few reported cases have occurred in indi-
viduals with occupational asbestos exposure (Kahn et al., 1980;
Beck et al., 1982; Thomason et al., 1994; Fujiwara et al., 2005),
it appears that the vast majority of recently reported cases had
no known asbestos exposure (Quinn et al., 2000; Hirano et al.,
2002; Reis-Filho et al., 2002; Val-Bernal et al., 2002; Susman et al.,
2004; Yakirevich et al., 2004; Erdogan et al., 2005; Lagrotteria
et al., 2005; Maruyama et al., 2006; Molina Garrido et al., 2006;
Doval et al., 2007; Vornicu et al., 2007; Akamoto et al., 2008;
Santos et al., 2008), and many were reported in younger indi-
viduals (e.g., age 19–50 years). Malignant mesothelioma of the
pleural cavity was also reported to occur in a 15-year old boy with
rheumatic heart disease and a prosthetic aortic valve implant; this
child was reported to have no history of asbestos or chemical
exposure (Tewari et al., 1989).
As reviewed by Kumar et al. (2005b), the heart is one of the
first organs to form and function during early embryonic devel-
opment. Developmental errors in mesenchymal tissue migration
are just one example of genetic errors leading to certain types of
congenital heart disease, e.g., involving various anomalies of the
outflow tract, some due to failure of fusion and others due to
failure of septation. Parallel to the genesis of some extragonadal
GCTs from abnormal germ cell migration along the embryologi-
cal urogenital ridge, some congenital heart defects may be caused
by abnormal development of neural crest-derived cells, whose
migration into the heart is required for proper formation of the
outflow tracts. Many congenital heart defects are related to tri-
somies of chromosomes 13, 15, 18, and 21, and deletions in
chromosome 22 (22q11.2) are thought to play a major role in
congenital heart disorders of the conotruncus and the brachial
arches (Kumar et al., 2005b). Accordingly, it seems appropriate
that identification of a case of malignant mesothelioma involving
congenital heart disease would initiate genetic screening to help
define the common congenital defects that may relate to the onset
of both diseases in the same individual. Further research is also
recommended to examine the incidence of malignant mesothe-
lioma among individuals with various forms and severity of
congenital heart disease, and perhaps also in relation to rheumatic
heart disease.
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SYNOVIAL SARCOMAS PRESENTING AS MESOTHELIOMA
There is no demonstrated association between synovial sarcoma
and asbestos exposure, although synovial sarcoma of the pleura
is difficult to distinguish from sarcomatoid mesothelioma with-
out the use of genetic screening (Nicholson et al., 1998; Cappello
and Barnes, 2001; Colwell et al., 2002; Weinbreck et al., 2007).
These tumors are thought to originate from primitive pluripotent
mesenchyme cells capable of sarcomatous differentiation. This
tumor can be highly aggressive, involving metastases to distant
locations (Siegel et al., 2007; Eilber and Dry, 2008), and consis-
tent with this they have been observed to occur in tissues with
little or no associated synovium. Indeed, synovial sarcoma does
not arise from or differentiate toward synovium—it is an unfor-
tunatemisnomer since the vast majority arise in deep soft tissue of
extremities, especially around the knee. Because of this it has been
proposed that synovial sarcoma be renamed as carcinosarcoma or
spindle cell carcinoma of soft tissue due to its immunoreactivity
to cytokeratins and EMA. Relevant to mistaken pleural mesothe-
liomas, synovial sarcomas have been prominently noted to occur
in the pleural cavity (Gaertner et al., 1996; Nicholson et al., 1998;
Caliandro et al., 2000; Cappello and Barnes, 2001; Colwell et al.,
2002; Vohra et al., 2004; Lee et al., 2006; Tsukioka et al., 2006;
Galetta et al., 2007; Iwata et al., 2007; Mukhopadhyay and Aubry,
2007; Satoh et al., 2007; Weinbreck et al., 2007), as well as in the
lung (Hosono et al., 2005; Taylor et al., 2005). Other reported
sites include the peritoneal cavity (Vera et al., 2006; Gofman et al.,
2007), and the stomach (Makhlouf et al., 2008).
Synovial sarcoma is a relatively rare malignancy that typically
occurs in adolescents and young adults between the ages of 15
and 50 years of age and most commonly affects the extremi-
ties in the vicinity of large joints such as the knee or the thigh
(Cadman et al., 1965; Cordon-Cardo, 1997; Nicholson et al., 1998;
Cappello and Barnes, 2001; Kumar et al., 2005c) and the hands or
feet (Michal et al., 2006). Because synovial sarcoma can be dif-
ficult to distinguish from reactive mesothelial proliferation and
sarcomatoid mesothelioma by use of histology and immunohis-
tochemical markers alone (Shiraki et al., 1989; Moran et al., 1992;
Nicholson et al., 1998; Miettinen et al., 2001; Carbone et al.,
2002; Gladish et al., 2002; Vohra et al., 2004; Taylor et al., 2005;
Michal et al., 2006; Rdzanek et al., 2006), it represents another
alternative carcinoma to consider when evaluating suspected sar-
comatoid mesothelioma cases. This has been particularly true
since the discovery of highly specific genetic lesions [t(x;18), SYT-
SSX1, SSX2, and SSX4 fusion genes] in synovial sarcoma tumors
that clinically distinguish this particular this tumor type (Colwell
et al., 2002; Amary et al., 2007; Weinbreck et al., 2007). Indeed,
Sandberg (2002) provides a summary of specific chromosomal
translocations corresponding to a variety of soft tissue sarcomas
including synovial sarcoma where—the translocation is the sole
cytogenetic anomaly, indicating the probable causative role of this
translocation in the genesis of these tumors. In synovial sarcoma,
the normal SYT gene encodes a transcription factor whereas the
SSX1 and SSX2 genes produce proteins that are transcription
inhibitors. The available evidence suggests that the specific type of
translocation may be related to the aggressiveness of the synovial
sarcoma and its prognosis. The most common sites of metas-
tases are the lung/mediastinum, the skeleton, and regional lymph
nodes (Hosono et al., 2005; Kumar et al., 2005c; Michal et al.,
2006).
Two additional soft tissue sarcomas should be mentioned
here because they have the potential to occur as poorly dif-
ferentiated metastatic tumors with staining characteristics that
are difficult to distinguish from sarcomatoid mesothelioma, but
they can be positively identified by their unusual chromosomal
alterations (Kumar et al., 2005a). Desmoplastic small round cell
tumor, a tumor of unknown hisotogenesis in the peritoneum,
shows a specific translocation [t(11;22)(p13;q12)], involving the
EWS-WT-1 gene fusion product in 90% of cases. Endometrial
stromal sarcoma, a tumor that may occur as distant metastases
decades after hysterectomy, also shows a specific translocation
[t(7;17)(p15;q21)], involving JAZF1-JJAZ1 gene fusion product
in about 65% of cases. These tumors are relatively rare sarcomas
that have sufficiently unique markers to distinguish the origin of
poorly differentiated spindle cell tumors that may be mistaken as
mesotheliomas.
INHERITED CANCER SUSCEPTIBILITY SYNDROMES AND
MESOTHELIOMA
Certain inherited disorders produce multiple cancers that are
prone to develop chromosomal instability and present at a
late stage with histological features that mimic disseminated
mesothelioma (Hawley and Pandolfi, 2008). Two examples
of such inherited disorders are Multiple Endocrine Neoplasia
Syndrome-1 (MEN-1) and Hereditary Non-Polyposis Colon
Cancer (HNPCC). Both syndromes are known to have diagnos-
tic genetic mutations in somatic cells that identify the syndrome
and overt clinical outcome which consists of multiple, but often
survivable, cancers in affected subjects and their blood relatives.
MEN-1 involves a germline mutation at the 11q13 (a tumor
suppressor gene) which encodes for a protein menin and is asso-
ciated with increased risk of parathyroid, endocrine (thyroid,
prostate, testicular, breast, and ovarian), pancreas, and pituitary
neoplasia (mostly adenomas) (Mayer, 2005; Morin et al., 2005).
MEN-1 is known to occur in conjunction with Zollinger-Ellison
Syndrome (ZES) in both sporadic and heritable forms, with an
estimated 50% penetration among blood relatives. ZES leads to
the formation of gastrinomas in the pancreas and/or duodenum
that lead to hypergastrinemia and intractable peptic ulcer dis-
ease, however the most common and earliest manifestation is
usually primary hyperparathyroidism. Clinical markers for ZES
are elevated fasting gastrin (>150 pg/ml) and sometimes hyper-
parathyroidism resulting in elevated blood calcium, parathyroid
hyperplasia, and other sequelae (Goyal, 2005). The late stages
of MEN-1 are associated with increasing chromosomal instabil-
ity among tumors that may have metastasized to other tissues
decades earlier, or involving proliferation from surgical scars of
the stomach, since the only way to resolve duodenal hypergas-
trinemia is with distal gastrectomy. Late stage tumors of MEN-1
patients have been associated with chromosomal instability that
may plausibly lead to local tissue invasion and conversion to
mixed neoplastic cell types including soft tissue sarcomas that
maymimicmesotheliomas. Thus, it is suggested that persons with
characteristic prior cancers and/or ZES and distal gastrectomy
who present with apparent mesothelioma should be tested for the
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somatic cell mutation (11q13) of the MEN-1 tumor suppressor
gene, in addition to testing for other translocations that may be
diagnostic for various types of soft tissue sarcoma that may be
relevant to the tumor/site (Sandberg, 2002).
Similarly, HNPCC involves germline mutations at certain loci
(2p16, 3p21.3, and 7p22) that are associated with the formation of
carcinoid tumors of the duodenum and ascending colon (Mayer,
2005; Morin et al., 2005; Hawley and Pandolfi, 2008). As with
MEN-1, this germline mutation is thought to have a high pen-
etration rate, and often involves multiple additional tumor sites
including endometrial, ovarian, stomach, small bowel, and ureter
carcinoma. Also, late stage tumors in HNPCC patients are asso-
ciated with chromosomal instability that may plausibly lead to
local tissue invasion and conversion to mixed neoplastic cell types
including soft tissue sarcomas that may mimic mesotheliomas.
Thus, persons with characteristic prior cancers who present with
apparent mesothelioma should be tested for the somatic cell
mutations of HNPCC, in addition to testing for other translo-
cations that may be diagnostic for various types of soft tissue
sarcoma that may be relevant to the tumor/site (Sandberg, 2002).
DISCUSSION
Based on the preceding research summary, a preliminary genetic
screening matrix has been outlined in Table 1 that could be used
as a starting point for further characterizing and understand-
ing the clinical and genetic features of malignant mesothelioma
and other primary cancers that may sometimes mimic asbestos-
related mesothelioma. As noted in the Introduction, there are
many additional candidate features that could be added to Table 1
as the associations between mesothelioma and various genetic
Table 1 | Suggested matrix for genetic screening of suspected malignant mesothelioma cases.
Patient type Specifc genetic lesions Rationale and possibly associated clinical eatures
All Patients Deletions in tumor tissue DNA at
1p21-p22, 3p21.3, 9p14/p16, 6q14-q21,
6q16.6-q21, 6q21-q23.2, 6q25,
15q11.1-q15; and loss of a copy of
chromosome 22
Most commonly associated genetic lesions identified in
mesothelioma but overlapping with other cancer types. Monitor
statistical associations to identify which specific deletions are most
specific and diagnostic for general and site-specific mesothelioma
Patients with prominent
epithelioid histology and primary
midline or mediastinal tumor
occurrence
Germ cell tumor markers in tumor tissue:
iso12p, often multiple copies; widespread
gene loss across most chromosome arms,
and non-random gains in chromosomes 1,
7, 12, 21, 22, and X
Germ cell tumors can metastasize widely, and extragonadal germ
cell tumors are known to occur in nodes and tissues along the
embryonic urogenital ridge from the cranium to the presacral region
(C6 to L4) due to abnormal germ cell migration. Treatment and
prognosis may be very different compared to primary
mesothelioma. Clinical correlates may include history of
cryptorchidism and family history of testicular cancer or male sibling
leukemia or lymphoma
Patients with epithelioid histology
and primary peritoneal tumor
occurrence and a family history or
personal history of breast and/or
ovarian cancer
Testing of tumor tissue and somatic cells
for mutations in BRCA-1 and BRCA-2 for
meso with history of ovarian or breast
cancer; mutations at 2p16, 3p21.3, 7p22
for history of multiple endocrine cancer;
and del(22q11.2) and trisomy 13, 15, 18 or
21 and for peritoneal meso with heart
valve defects
Serous epithelioid cancers from mullerian tissues can present as
peritoneal metastases from occult tumors of mullerian tissues (e.g.,
ovarrian surface epithelium, fallopian tubes and fimbria) and are
difficult to distinguish from mesothelioma without thorough
pathological evaluation. Serous carcinomas may occur sporadically
or with familial syndromes including Breast Ovarian Cancer
Syndrome, Site Specific Ovarian Cancer Syndrome, and Hereditary
Non-Polyposis Colon Cancer
Patients with prominent spindle
cell histology and possible history
of severe synovial trauma and/or
recurrent synovial growths
Synovial sarcoma markers in tumor tissue:
translocation (x;18) leading to SSX1 or
SSX2 fusion gene transcripts
Synovial sarcomas generate from mutation of mesenchymal
tissues, can metastasize to locations mimicking true mesothelioma,
and can have widely varied clinical presentation and prognosis.
Genetic tracking of these tumors may assist to better characterize
primary site, treatment and prognosis. Recurrent synovial or
ganglionic cysts, and severe or repeated trauma to synovial tissues
may reflect higher risks
Patients with personal and/or
family history of certain additional
primary cancers (e.g., thyroid,
prostate, testes, breast, ovary,
pancreas, GI tract, ureter,
endometrium)
Somatic cell mutations: 11q13 for history
of possible multiple endocrine neoplasia/
Zollinger-Ellison Syndrome, MEN-1/ZES;
and 2p16, 3p21.3, 7p22 mutations for
history of possible hereditary
non-polyposis colon cancer, HNPCC
In advanced stages of invasive/metastatic cancers from MEN-1 or
HNPCC, chromosomal instability may lead to histopathologic
features that mimick mesothelioma. Genetic tracking may assist to
better characterize primary site, treatment and prognosis.
MEN-1/ZES includes diagnostic gastrinomas of
duodenum/pancrease with intractable peptic ulcer disease often
requiring gastrectomy. HNPCC includes diagnostic carcinoid tumors
of duodenum and ascending colon
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markers are further clarified. This preliminary matrix could assist
in developing future research plans and incorporating other clin-
ical observations that may help to fulfill the goal of obtaining
unambiguous diagnostic criteria for various forms of malignant
mesothelioma and tumors that may mimic mesothelioma.
Diagnosing a tumor as mesothelioma based on histologic and
immunohistochemical staining characteristics alone can lump
together several mesenchymal tumor types of different origins
that should be treated as distinct clinical entities with unique
risk factors, prognosis, and best treatment modalities. Several
mesenchymal tumors that are difficult to distinguish based on
histology and staining characteristics are already known to be
distinguished by genetic markers in somatic or tumor cells.
The number of mullerian or germ cell tumors, advanced
metastatic tumors, or mistaken synovial sarcomas that may have
no plausible connection to asbestos exposure will remain obscure
without appropriate research that supports a more definitive,
evidence- based decision matrix for correct diagnosis. While the
prognosis of any given individual’s cancer can be difficult to
predict, this research may identify genetic and/or clinical charac-
teristics that presently, or in the future, will aid in more accurate
prognostic predictions and perhaps more tumor-specific and effi-
cacious treatments. For example, some forms of synovial sarcoma
that remain circumscribed and relatively indolent are survivable
without the aggressive clinical interventions typical of the treat-
ment of malignant mesothelioma. Similarly, the confirmation of
germ cell tumor origins would call formore focused clinical inves-
tigations and interventions that greatly differ from mesothelioma
treatments. By adopting better diagnostic criteria for those mes-
enchymal tumor subtypes that may bemistaken as mesothelioma,
physicians will improve epidemiologic estimates of the incidence
and prevalence of the tumor types discussed above. Thus, this
approach would ultimately improve dose-response relationships
in the low dose region for asbestos and mesothelioma as well as
that of other apparent risk factors for this deadly disease.
As discussed earlier, the proportion of future mesothelioma
cases that can be credibly attributed to asbestos is likely to lessen
because the highly potent amphibole exposures were largely cur-
tailed in the 1960s and the typical latency period of 20–40 years
since first exposure has now transpired. The incidence of pleural
mesotheliomas that are more specifically associated with asbestos
is projected to continue declining, while peritoneal mesothelioma
incidence (associated primarily with non-asbestos causes) has
been essentially flat for decades (Teta et al., 2008; Moolgavkar
et al., 2009). Parallel to mesothelioma risk trends, asbestosis is a
fibrotic interstitial lung disease with a comparable latency period
that has also generally diminished in both incidence and clinical
severity in the past two decades. This trend has raised questions
about howmany valid asbestosis cases arise from the many claims
that today are often based solely on equivocal radiographic find-
ings and questionable occupational history of asbestos exposure
(Bang et al., 2008; Mizell et al., 2009; Harding and Darnton,
2010).
Physicians are urged to recognize that the proportion of
mesothelioma cases unrelated to asbestos will likely increase
in coming decades, and that better vigilance will be needed
for proper diagnosis, treatment, and prevention. This will
undoubtedly involve the development and use of more definitive
diagnostic tools like genetic screening that can help differentiate
asbestos-related mesothelioma from other mesenchymal tumor
subtypes or advanced metastatic tumors that can mimic the
histopathological presentation of mesothelioma.
A national or international registry-based mesothelioma
research program may be an achievable and appropriate means
for augmenting the knowledge base on clinical features and
genetic markers for distinguishing specific forms of mesothe-
lioma and tumors that may mimic mesothelioma. Since the
annual number of mesothelioma cases is relatively small, the
scope of research each year may be reasonably defined. Incident
case detection could be linked to existing state and/or national
cancer registries, with the registry research program overseen by
a steering committee with outside peer review resources. A work-
ing group could be tasked with developing appropriate research
protocols for collection of needed clinical and family history
information in addition to samples of tumor tissue and somatic
cells for genetic screening. The scope of analysis and quality con-
trol procedures of the working group should be clearly defined
and transparent, with assurance of evidence-based data analysis
and outside peer review of findings in a manner that also assures
objectivity and patient privacy.
In conclusion, the identification of relatively specific clini-
cal features and genetic markers that may avoid misdiagnosis
of mesothelioma and other mesenchymal tumor subtypes or
advanced metastatic tumors is an important future research need.
Currently, the diagnosis of mesothelioma rests largely on his-
tology and staining patterns that are sometimes inconclusive.
It is recommended that further research be directed at iden-
tifying those genetic and clinical features unique to malignant
mesothelioma and the cancers that may mimic its histopathology.
This research could be fostered through a national or inter-
national mesothelioma registry with requisite medical history
questionnaire and tumor/somatic tissue submission, hopefully
leading to more specific diagnostic tools, better disease classifi-
cation and incidence data, and a uniform and enhanced database
for understanding the natural history and prognosis of various
mesothelioma subtypes.
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